GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Pretax Margin %

Amplia Therapeutics (Amplia Therapeutics) Pretax Margin % : % (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Amplia Therapeutics's Pre-Tax Income for the six months ended in Sep. 2023 was $-0.73 Mil. Amplia Therapeutics's Revenue for the six months ended in Sep. 2023 was $0.00 Mil. Therefore, Amplia Therapeutics's pretax margin for the quarter that ended in Sep. 2023 was %.

The historical rank and industry rank for Amplia Therapeutics's Pretax Margin % or its related term are showing as below:


INNMF's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -176.72
* Ranked among companies with meaningful Pretax Margin % only.

Amplia Therapeutics Pretax Margin % Historical Data

The historical data trend for Amplia Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Pretax Margin % Chart

Amplia Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amplia Therapeutics Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amplia Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Amplia Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Pretax Margin % falls into.



Amplia Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Amplia Therapeutics's Pretax Margin for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-4.167/0
= %

Amplia Therapeutics's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.726/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (OTCPK:INNMF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Amplia Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics (Amplia Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines